Bioatla News

News

Ticker

BCAB

ISIN

US09077B1044

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Bioatla Eulerpool News

Bioatla Stock News

Bioatla is being monitored by journalists and investors worldwide. We gather the latest Bioatla news here.

February 9·
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
February 9·
Benzinga
Why STMicroelectronics Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
February 2·
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
January 5·
Benzinga
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
December 31·
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 13·
SeekingAlpha
BioAtla, Inc. 2025 Q3 - Results - Earnings Call Presentation
November 13·
SeekingAlpha
BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript
November 13·
Benzinga
Earnings Scheduled For November 13, 2025
October 23·
Benzinga
BioAtla Presents Ozuriftamab Vedotin Clinical Data Targeting ROR2 In HPV+ Head & Neck Cancer at IPVS Conference 2025
September 8·
Yahoo
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA
August 13·
Benzinga
JMP Securities Downgrades BioAtla to Market Perform
August 9·
SeekingAlpha
BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript
June 2·
Yahoo
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen
June 2·
Benzinga
Reported Earlier: BioAtla Reports 45% ORR And 100% DCR In Heavily Pretreated HPV+ OPSCC Patients In Phase 2 Trial Of Ozuriftamab Vedotin
May 7·
Benzinga
BioAtla shares are trading higher after the company reported better-than-expected Q1 financial results.
May 7·
Yahoo
BioAtla Inc (BCAB) Q1 2025 Earnings Call Highlights: Promising Clinical Progress Amid Financial ...
May 6·
Yahoo
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress
April 29·
Yahoo
BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025
April 24·
Yahoo
BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
April 23·
Yahoo
BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Bioatla Stock Press Releases

Bioatla regularly publishes news on the company's website that are relevant for investors.

Bioatla News 2026

This page contains all current news, analysis and press releases for Bioatla stock (BCAB, ISIN: US09077B1044). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Bioatla.

Bioatla Stock

Bioatla Bioatla Inc, trading under ticker BCAB, is a US-based biotechnology company headquartered in San Diego. It operates in the Health Care sector with a focus on developing antibody-based therapeutics for solid tumor cancers. The company has 66 employees and completed an IPO on December 16, 2020. Its product pipeline includes BA3011, a conditionally active biologics antibody-drug conjugate targeting AXL, and BA3021, targeting ROR2. Other candidates are BA3071, an anti-CTLA-4 antibody, and BA3182, a dual-CAB therapy for adenocarcinoma.